Literature DB >> 8105420

Neurotransmitters in basal ganglia and cortex of Alzheimer's disease with and without Lewy bodies.

P J Langlais1, L Thal, L Hansen, D Galasko, M Alford, E Masliah.   

Abstract

We measured the concentrations of the monoamines, their precursors, and their metabolites, and the activity of choline acetyltransferase (ChAT) in basal ganglia and cortical regions of postmortem brains from cases with histologically verified pure Alzheimer's disease (AD), AD with diffusely distributed Lewy bodies (Lewy body variant [LBV]), and normal controls. Dopamine and homovanillic acid (HVA) were severely depleted in basal ganglia of the LBV cases but were not significantly altered in pure AD cases; tyrosine hydroxylase levels in putamen were also significantly reduced in LBV but not AD cases. These reductions in basal ganglia dopamine and HVA suggest that LBV cases have a level of dopamine depletion similar to Parkinson's disease (PD). Additionally, ChAT activity in caudate and norepinephrine concentration in putamen were significantly reduced in the LBV group, which may have contributed to the absence of resting tremor and the milder presentation of parkinsonian features in this group compared with classic PD. In frontal, parietal, and temporal cortex, activity of ChAT in the LBV group was significantly reduced compared with controls and lower than in pure AD.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8105420     DOI: 10.1212/wnl.43.10.1927

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  25 in total

1.  Dementia with lewy bodies: diagnosis and management for primary care providers.

Authors:  Melanie Zupancic; Aman Mahajan; Kamna Handa
Journal:  Prim Care Companion CNS Disord       Date:  2011

2.  Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline.

Authors:  Lani K Clinton; Mathew Blurton-Jones; Kristoffer Myczek; John Q Trojanowski; Frank M LaFerla
Journal:  J Neurosci       Date:  2010-05-26       Impact factor: 6.167

3.  Differences in MR features of the substantia innominata between dementia with Lewy bodies and Alzheimer's disease.

Authors:  Haruo Hanyu; Yuriko Tanaka; Soichiro Shimizu; Hirofumi Sakurai; Toshiko Iwamoto; Kimihiko Abe
Journal:  J Neurol       Date:  2005-03-18       Impact factor: 4.849

4.  [Dementia with Lewy bodies. Clinical improvement under treatment with an acetylcholinesterase inhibitor].

Authors:  M Omerovic; S J Teipel; T Hampel
Journal:  Nervenarzt       Date:  2007-09       Impact factor: 1.214

Review 5.  Dementia with Lewy bodies: clinical features and treatment.

Authors:  S Campbell; S Stephens; C Ballard
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

6.  Effect of α-synuclein on amyloid β-induced toxicity: relevance to Lewy body variant of Alzheimer disease.

Authors:  Rosa Resende; Sueli C F Marques; Elisabete Ferreiro; Isaura Simões; Catarina R Oliveira; Cláudia M F Pereira
Journal:  Neurochem Res       Date:  2013-02-07       Impact factor: 3.996

7.  Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand.

Authors:  Z Walker; D C Costa; R W H Walker; K Shaw; S Gacinovic; T Stevens; G Livingston; P Ince; I G McKeith; C L E Katona
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-08       Impact factor: 10.154

8.  Focal atrophy on MRI and neuropathologic classification of dementia with Lewy bodies.

Authors:  Kejal Kantarci; Tanis J Ferman; Bradley F Boeve; Stephen D Weigand; Scott Przybelski; Prashanthi Vemuri; Melissa E Murray; Melissa M Murray; Matthew L Senjem; Glenn E Smith; David S Knopman; Ronald C Petersen; Clifford R Jack; Joseph E Parisi; Dennis W Dickson
Journal:  Neurology       Date:  2012-07-25       Impact factor: 9.910

9.  Amyloid-β deposition and regional grey matter atrophy rates in dementia with Lewy bodies.

Authors:  Lidia Sarro; Matthew L Senjem; Emily S Lundt; Scott A Przybelski; Timothy G Lesnick; Jonathan Graff-Radford; Bradley F Boeve; Val J Lowe; Tanis J Ferman; David S Knopman; Giancarlo Comi; Massimo Filippi; Ronald C Petersen; Clifford R Jack; Kejal Kantarci
Journal:  Brain       Date:  2016-07-24       Impact factor: 13.501

10.  Anticholinergic therapy and dementia in patients with Parkinson's disease.

Authors:  M Pondal; T Del Ser; F Bermejo
Journal:  J Neurol       Date:  1996-07       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.